Navigation Links
Treatment Adherence Emerging as Critical Theme in Improving Quality and Cost of US Healthcare
Date:4/24/2013

will emerge as an essential component in delivering positive outcomes across these areas and beyond.  "An effective strategy that motivates patients to follow prescribed treatment or a recommended health plan will decrease medication waste and overall healthcare cost, lower readmissions, and improve patient outcomes."

Understanding Intentional Nonadherence 
According to Dr. Eliasson, healthcare companies also need to have a greater awareness of the role of intentional nonadherence within the patient population. Studies show the majority of patients who don't follow their treatments are doing so on purpose – they may not believe the treatments work or that the benefits outweigh the side effects. 

"These patients need more than reminder calls and pillbox alarms," said Dr. Eliasson. "They need specific strategies and education to change their beliefs about their illness – and to motivate them to manage their health for the long term."

For more information on treatment adherence in healthcare, visit www.atlantishealthcare.com.

To learn about the World Health Care Congress, visit www.worldhealthcarecongress.com

About Atlantis Healthcare 
Established in 1993, Atlantis Healthcare creates and executes tailored patient support programs and personalized interventions to address treatment adherence across a wide range of chronic and acute diseases, worldwide.  Led by one of the world's largest health psychology teams, our patient-centric approach is designed to improve health outcomes and deliver optimal value for all healthcare stakeholders. www.atlantishealthcare.com.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.  
Lina Eliasson 

SOURCE Atlantis Healthcare
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
(Date:1/15/2014)... Inc. (Nasdaq: ECTE ) ("Echo"), a medical ... non-invasive, wireless continuous glucose monitoring system, today announced that ... CEO of Echo Therapeutics, will present at "TEN", Noble ... Mr. Doman will make a corporate presentation to ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... 5, 2011 Nektar Therapeutics (Nasdaq: NKTR ... patients in a Phase 2 clinical study evaluating single-agent ... of 33 women in the study with prior Doxil® ... response rate using either RECIST 1.0 criteria (response by ...
... CHICAGO, June 4, 2011 Genomic Health, Inc. (Nasdaq: ... studies being presented at the American Society of Clinical ... study confirming the performance of the Onco type ... predictor of recurrence risk in stage II colon cancer. ...
Cached Medicine Technology:NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 2NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 3NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 4NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 5NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 6NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 7NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 8Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 2Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 3Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 4Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 5Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 6Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 7Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 8Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 9
(Date:7/11/2014)... The Williams Rejuva Center excited to ... patient’s unique treatment regime. Using the Vectra 3D ... trouble areas can be quickly created. The evaluation ... , Vectra 3D is a cutting-edge computer imaging system. ... a quick ‘snapshot’ of the skin to determine the ...
(Date:7/11/2014)... 11, 2014 Even the hot Texas sun ... Elementary School . The school had previously invested ... equipment from APCPLAY, but recently asked for an innovative ... , Godley Elementary School chose a Rectangular Shade from ... for children on their playground. The shade measures 24’W ...
(Date:7/11/2014)... July 11, 2014 Shu Cosmetic ... perineplasty for each qualifying patient undergoing a ... been performing laser vaginal rejuvenation, an advanced type ... The LVR procedure decreases the internal and external ... muscle tone, strength, and control, resulting in enhanced ...
(Date:7/11/2014)... ASHBURN PSYCHOLOGICAL AND PSYCHIATRIC SERVICES , On July 1st, Senate ... disability or autism to have a special code placed on ... law enforcement or first responders that they are dealing with ... a central Virginia mother, Ms. Pam Mines, who wanted to ... JP. During a news conference after the law passed, ...
(Date:7/10/2014)... (PRWEB) July 11, 2014 Karen Middleton, ... President and CEO of Planned Parenthood of the Rocky ... Senator Mark Udall and Representative Diana DeGette were in ... Court’s Hobby Lobby decision and keeping bosses out of ... representatives listened to the president today in Denver addressing ...
Breaking Medicine News(10 mins):Health News:Williams Rejuva Center Includes Innovative Computer Imaging 2Health News:Cool Fun Under the Texas Sun: Godley Elementary School Purchases Shade Structure from APCPLAY© 2Health News:Shu Cosmetic Surgery of Twin Cities Now Offers Complimentary Perineoplasty in Laser Vaginal Rejuvenation 2Health News:Shu Cosmetic Surgery of Twin Cities Now Offers Complimentary Perineoplasty in Laser Vaginal Rejuvenation 3Health News:Recent Special “Autism” Code on Virginia Driver’s Licenses and ID Cards Goes into Law: Helpful or Discriminatory for Individuals on the Autistic Spectrum? 2Health News:Recent Special “Autism” Code on Virginia Driver’s Licenses and ID Cards Goes into Law: Helpful or Discriminatory for Individuals on the Autistic Spectrum? 3Health News:Naral Pro-Choice Colorado & Planned Parenthood Of The Rocky Mountains Statement On Udall & Degette Staying In Dc To Introduce Legislation 2
... ... for the Apple® iPhone. Module is the world’s first all-purpose iPhone case to ... ... February 24, 2010 -- Dacha Works LLC , the mobile computing accessories company, ...
... ... Company’s Future Growth , ... (PRWEB) March 17, 2010 -- Group Logic, a leading provider of desktop ... the company’s new chief executive officer (CEO). As a software industry veteran, Broderick ...
... Highly educated white men most likely to be tipplers, study ... to two-thirds (61 percent) of American adults consider themselves drinkers, ... likely to drink alcohol than women, and people with more ... of U.S. residents say they,ve abstained their whole lives. ...
... ... pharmacists with valuable information on topics such as operations management, economic analysis, reimbursement ... human resource strategies – vital competencies for pharmacy leaders and managers. , ... Sudbury, MA ...
... ... and high rates of asthma in Washington, DC. , ... Washington, DC (Vocus) March 17, 2010 -- Researchers ... asthma in metropolitan Washington, DC, are significantly more likely to have low levels of ...
... Worldwide Edition for his outstanding contributions and achievements in the field of healthcare. , ... , ... ... , ...
Cached Medicine News:Health News:Dacha Works Introduces Module- A Revolution In iPhone Case Design 2Health News:Group Logic, Inc. Appoints New CEO 2Health News:Group Logic, Inc. Appoints New CEO 3Health News:6 Out of 10 American Adults Drink 2Health News:New Book Reviews Core Competencies for Pharmacy Leaders 2Health News:New Book Reviews Core Competencies for Pharmacy Leaders 3Health News:New Book Reviews Core Competencies for Pharmacy Leaders 4Health News:Study: Low Levels of Vitamin D Linked to Higher Rates of Asthma in African American Kids 2Health News:Study: Low Levels of Vitamin D Linked to Higher Rates of Asthma in African American Kids 3Health News:Dr. Mark Russell Recognized By Strathmore's Who's Who Worldwide Publication 2
... for catheter or instrument introduction. The ... be peeled away and removed. The ... instrument to be introduced should be ... the sheath. Supplied sterile in peel-open ...
Used for stenting the urethra after hypospadias or epispadias repair and to provide post-operative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
... Used to provide ... or epispadias repair. The ... to partially close during ... urethra while maintaining urethral ...
... temporary internal drainage from ... the bladder. Supplied sterile ... for one-time use. CAUTION: ... C-Flex® and Sof-Flex® stents ...
Medicine Products: